Transparency notification BlackRock, Inc.

Brussels (Belgium), 26 September 2024 – 20:00 (CEST) – Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 23 September 2024.

BlackRock, Inc. notified that, following a disposal of UCB shares with voting rights or assimilated financial instruments by its affiliates, its shareholding in UCB SA decreased and crossed the 5% threshold downwards on 20 September 2024.

On 20 September 2024, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 613 336 UCB shares with voting rights or assimilated financial instruments, representing 4.94% of the total number of shares issued by the company (194 505 658), versus 5.04% (9 801 293 UCB shares or assimilated financial instruments) in the previous notification dated 20 September 2024.

2. Content of the notification

- **Reason for the notification**: Acquisition or disposal of voting securities or voting rights, acquisition or disposal of financial instruments that are treated as voting securities.
- Notification by: A parent undertaking or a controlling person.
- Persons subject to the notification requirement:



Name	Address (for legal entities)
BlackRock, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG	Lenbachplatz 1 1st Floor, Munich, 80333-MN3, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Investment Management (Australia) Limited	Level 37 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan
Aperio Group, LLC	3 Harbor Dr Suite 204, Sausalito, CA 94965, U.S.A.
SpiderRock Advisors, LLC	Corporation Service Company, 251 Little Falls Drive, Wilmington, DE 19808, U.S.A.

• Date on which the threshold is crossed: 20 September 2024.

• Threshold crossed (in %): 5%.

Denominator: 194 505 658.

• Notified details:



A) Voting rights		Previous notification		After the transaction					
		# of voting rights		# of voting right		s	% of voting rights		
Holders of voting rights				Linked to	securities		nked to the ecurities	Linked to securities	Not linked to the securities
BlackRock, Inc.		0			0			0,00%	
BlackRock (Netherlands) B.V.		3.219		3.	3.219			0,00%	
BlackRock (Singapore) Limited		4.015		4.	690	90		0,00%	
BlackRock Advisors (UK) Limited		1.525.035	1.525.035		21.820			0,78%	
BlackRock Advisors, LLC		87.072		87	7.072			0,04%	
BlackRock Asset Management Canada Limited		131.347		13	131.298			0,07%	
BlackRock Asset Management Deutschland AG		178.339		178	78.545			0,09%	
BlackRock Asset Management North Asia Limited		3.524		3.	3.524			0,00%	
BlackRock Financial Management, In	c.	72.623		72	.623			0,04%	
BlackRock Fund Advisors	und Advisors		2.532.434		527.431			1,30%	
BlackRock Institutional Trust Compar National Association	ıy,	1.621.812		1.61	8.322			0,83%	
BlackRock Investment Management (Australia) Limited		52.146		52	.146			0,03%	
BlackRock Investment Management (UK) Limited		2.742.680		2.56	2.568.195			1,32%	
BlackRock Investment Management, LLC		563.601		562	562.667			0,29%	
BlackRock Japan Co., Ltd.		234.207		234	234.207			0,12%	
Aperio Group, LLC		39.982		39	.982			0,02%	
Subtotal		9.792.036		9.605.741				4,94%	
TOTAL		TOTAL			9.605.741		0	4,94%	0,00%
B) Equivalent financial instruments				After ti	ne transactio	on			
Holders of equivalent financial instruments		Type of financial instrument	Expira	ation date	Exercise pe		# of voting rig that may be acquired if the instrument exercised	he % of voting right	s Settlement
BlackRock Investment Management (UK) Limited	Securities Lent						596	0,00%	physical
BlackRock Financial Management, Inc.	Contract for Difference						643	0,00%	cash
BlackRock Institutional Trust Company, National Association	Contract for Difference						1.568	0,00%	cash
Aperio Group, LLC	Depo	Depositary Receipt					4.746	0,00%	
SpiderRock Advisors, LLC	Depositary Receipt						42	0,00%	
	TOTAL						7.595	0,00%	
	TOTAL (A & B)						# of voting rig	hts % of voting righ	ts
					CALCUI	CALCULATE 9.613.336		4,94%	



• Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the 'Chain of Control' tab.

 Additional information: The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going below 5%. Additionally, voting rights attached to shares for BlackRock, Inc. went below 5%.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following <u>link</u>.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following <u>link</u>.

For further information, contact UCB:

Investor Relations
Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

